42288-29-9

Upstream product

• 501008-39-5 ethyl 2-((3,5-dichlorophenyl)amino)acetate 
• 626-43-7 3,5-Dichloroaniline 

Downstream Products

• 1374243-23-8 tert-butyl 1-(2-(3,5-dichlorophenylamino)acetyl)-4-methylpiperidin-3-ylcarbamate 
• 1374242-67-7 tert-butyl (S)-1-(2-(3,5-dichlorophenylamino)acetyl)piperidin-3-ylcarbamate 
• 1374242-69-9 tert-butyl methyl((S)-1-(2-(3,5-dichlorophenylamino)acetyl)piperidin-3-yl)carbamate 
• 1374239-13-0 (S)-2-(3,5-dichlorophenylamino)-1-(3-(ethyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)ethanone 
• 1374239-47-0 1-(3-(1H-pyrazolo[3,4-d]pyrimidin-4-yl-N-methylamino)azepan-1-yl)-2-(3,5-dichlorophenylamino)ethanone 
• 1374242-83-7 2-(3,5-dichlorophenylamino)-1-(3-(7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)azepan-1-yl)ethanone 
• 1374242-86-0 2-(3,5-dichlorophenylamino)-1-(3-{methyl-[7-(tosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}azepan-1-yl)ethanone 
• 1374243-39-6 2-(3,5-dichlorophenylamino)-1-(6-(methyl(7-tosyl-7H-pyrrolo[2,3-d]pyrirnidin-4-yl)amino)-1,4-oxazepan-4-yl)ethanone 
• 1374241-92-5 (R)-2-(3,5-dichlorophenylamino)-1-(3-(methyl(7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)ethanone 
• 1374239-07-2 (R)-2-(3,5-dichlorophenylamino)-1-(3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)ethanone 
• 1374239-01-6 (S)-1-(3-(1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)piperidin-1-yl)-2-(3,5-dichlorophenylamino)ethanone 
• 1374239-34-5 1-{(S)-3-[(2-aminopyrimidin-4-yl)methylamino]piperidin-1-yl}-2-(3,5-dichlorophenylamino)ethanone 
• 1374242-70-2 2-(3,5-dichlorophenylamino)-1-((S)-3-(methylamino)piperidin-1-yl)ethanone 
• 1374239-27-6 1-((S)-3-(2-aminopyrimidin-4-ylamino)piperidin-1-yl)-2-(3,5-dichlorophenylamino)ethanone 

Relevant academic research and scientific papers

ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS

Disclosed herein are certain acetamido derivatives that are DNA Polymerase Theta (Polθ) inhibitors of Formula (I). Also, disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of Polθ such as cancer, including homologous recombination (HR) deficient cancers.

SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE

The present disclosure is generally directed to compositions useful in the inhibition of MetRS and methods for treating diseases that are ameliorated by the inhibition of MetRS.